Detecting minimal residual disease may be key to preventing ovarian cancer recurrence
August 27, 2025
Key takeaways:
- Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS.
- Many women who appeared in remission had surgically- or ctDNA-detected minimal residual disease.
UPDATES AND NEWS
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working | The New York Times
We can prevent ovarian cancer. Women deserve the option. | USA Today
Fallopian tube removal may lower ovarian cancer risk | Good Morning America
The Lustgarten Foundation and Break Through Cancer Announce New Clinical Trial Evaluating KRAS-targeted Immunotherapy Strategy for Pancreatic Cancer
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.
